tiprankstipranks
Egetis Therapeutics AB (SE:EGTX)
FRANKFURT:EGTX
Sweden Market
EGTX
Egetis Therapeutics AB
RESEARCH TOOLSreports

Egetis Therapeutics AB (EGTX) Income Statement

― Followers

Egetis Therapeutics AB Income Statement

Last quarter (Q4 2025), Egetis Therapeutics AB's total revenue was kr17.90M, an increase of 65.74% from the same quarter last year. In Q4, Egetis Therapeutics AB's net income was kr-119.70M. See Egetis Therapeutics AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
kr 62.40Mkr 46.10Mkr 57.60Mkr 22.50Mkr 38.24M
Gross Profit
kr 12.40Mkr 34.50Mkr -146.90Mkr -120.10Mkr -58.28M
Operating Expenses
kr 359.30Mkr 363.90Mkr 177.90Mkr 54.70Mkr 46.80M
Depreciation and Amortization
kr 0.00kr -100.00Kkr 3.60Mkr 2.70Mkr 2.46M
EBITDA
kr -346.90Mkr -317.40Mkr -319.10Mkr -191.00Mkr -101.90M
Operating Income
kr -346.90Mkr -329.40Mkr -324.80Mkr -198.10Mkr -105.68M
Other Income/Expenses
kr 4.80Mkr -13.80Mkr -2.00Mkr 4.30Mkr 1.18M
Pretax Income
kr -342.10Mkr -343.20Mkr -326.80Mkr -193.80Mkr -104.54M
Net Income
kr -342.50Mkr -343.60Mkr -326.90Mkr -189.50Mkr -104.73M
Per Share Metrics
Basic EPS
kr -0.93kr -1.12kr -1.27kr -0.98kr -0.58
Diluted EPS
kr -0.93kr -1.12kr -1.26kr -0.98kr -0.58
Weighted Average Shares Outstanding
 368.19M 306.54M 256.75M 194.24M 179.91M
Weighted Average Shares Outstanding (Diluted)
 368.19M 306.54M 260.01M 194.24M 179.91M
Currency in SEK

Egetis Therapeutics AB Earnings and Revenue History